Purified Analytes
Product name | Cancer antigen 15-3 (CA 15-3) | Cancer antigen 19-9 (CA 19-9) | Cancer antigen 125 (CA 125) |
Organ | Human liver metastases | Human ascites fluid | Human ascites fluid |
Purity | Highly purified | Highly purified | > 95% (SDS-PAGE) |
State | Liquid | Liquid | Liquid |
Activity | Typically > 500 kU/mL (Roche Elecsys EIA) | > 5,000 IU/mL (ELISA) | > 100 kU/mL (EIA) |
Purity information | High purity, low cross-contamination with other cancer antigens | Low cross-contamination: CA-125, CEA, CA 19-9 | Low cross-contamination: CA 15-3, CEA, CA 19-9 |
Purification | Gel filtration & ion-exchange chromatography |
|
|
Composition | Solution in phosphate buffered saline, pH 7.4 with sucrose and 0.05% sodium azide | Solution in 1 M sodium chloride, 1% Triton™ X-100, 0.05% sodium azide, pH 7.4 | Solution in phosphate buffered saline, pH 7.4 with 3% sucrose and 0.05% sodium azide |
Appearance | Clear and colorless | Cloudy, light yellow solution |
|
Storage | -20°C | -20°C | -20°C |
Recertification | 3 years | 2 years | 2 years |
Testing for infectious diseases | Negative or non-reactive at the donor level for anti-HIV 1 and 2, anti-HCV and HBsAg by FDA approved methods | Negative or non-reactive at the donor level for anti-HIV 1 and 2, anti-HCV and HBsAg by FDA approved methods | Negative or non-reactive at the donor level for anti-HIV 1 and 2, anti-HCV and HBsAg by FDA approved methods |
Synonyms | Tumour marker 19-9, CA 19-9, cancer antigen 19-9, carbohydrate antigen 19-9, sialyl Lewis (a) antigen | CA 15-3, tumour marker 15-3, mucin-1, MUC-1, breast carcinoma-associated antigen DF3, breast tumour antigen | MUCIN 16, muc16, CA-125, carbohydrate antigen 125, mucin-16 |